Gazanion Elodie auteur aut IRD Vergnes Baptiste auteur aut IRD Seveno Marie auteur aut IRD Garcia Deborah auteur aut IRD Oury Bruno auteur aut IRD Ait-Oudhia K. auteur aut IRD Ouaissi A. auteur aut IRD Sereno Denis auteur aut IRD text journalArticle eng text/pdf born digital access To improve the management of leishmaniasis, new drugs and/or alternative therapeutic strategies are required. Combination therapy of antileishmanial drugs is currently considered as one of the most rational approaches to lower treatment failure rate and limit drug resistance spreading. Nicotinamide (NAm), also known as vitamin B3 that is already is used in human therapy, exerts in vitro antileishmanial activity. Drug combination studies, performed on L. infantum axenic amastigotes, revealed that NAm significantly improves the antileishmanial activity of trivalent antimony in a synergistic manner while it shows additive activity with amphotericin B and slightly antagonizes pentamidine activity. NAm also significantly increases the toxicity of pentavalent antimony against the intracellular forms of L infantum, L amazonensis and L. braziliensis. The potential of NAm to be used as adjuvant during leishmaniasis chemotherapy is further discussed. specialized Nicotinamide Antimonials Leishmania Drug combinations 052 60 1 19-24 2011 1383-5769 https://www.documentation.ird.fr/hor/fdi:010053071 10.1016/j.parint.2010.09.005 1383-5769 [F B010053071] https://www.documentation.ird.fr/hor/fdi:010053071 https://www.documentation.ird.fr/intranet/publi/2011/03/010053071.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2011-04-07 2017-08-23 fdi:010053071 fre